Daniel Stoter

Daniel Stoter with JMP Securities inquired about the ongoing cross-selling benefits between AMDS and On-X, specifically trends in new surgeons' On-X utilization, and sought a detailed comparison of the eventual NEXUS commercial process to AMDS, including training intensity and specific rollout nuances.

Answer

Pat Mackin, CEO, confirmed that cross-selling benefits between AMDS and On-X are expected to be ongoing, as new relationships with aortic surgeons through AMDS provide opportunities to educate them and referring cardiologists on On-X data. He contrasted NEXUS commercialization with AMDS, noting AMDS's ease of use and broad applicability (1,000 centers) versus NEXUS's more intensive training requirements for highly skilled vascular surgeons in fewer, high-volume centers (couple hundred centers).